SCHEMBL10249397

SCHEMBL10249397

Cc1ccc(NCC(C)C)c(N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.50
TDP1 Q9NUW8 2/20 0.43
ALOX15 P16050 2/20 0.43
CYP3A4 P08684 2/20 0.43
THRB P10828 2/20 0.43
TP53 P04637 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 4/20 0.42
SLC6A4 P31645 2/20 0.42
IDO1 P14902 1/20 0.41
APP P05067 1/20 0.40
HSD17B10 Q99714 1/20 0.39
CA1 P00915 1/20 0.38
KDM4E B2RXH2 2/20 0.38
HTT P42858 2/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
GFER P55789 1/20 0.37
PLEC Q15149 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1341810 0.85 TDP1 (0.43) HDAC6TDP1ALOX15CYP3A4THRB
SCHEMBL12327881 0.81 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1IDO1HTTGAA
SCHEMBL18477378 0.80 AAK1 (0.44) THRBALDH1A1IDO1KDM4EHTT
SCHEMBL2722710 0.79 ALDH1A1 (0.56) HDAC6TDP1ALOX15CYP3A4THRB
SCHEMBL19366107 0.78 IDO1 (0.53) TDP1ALOX15TP53SMN1; SMN2ALDH1A1
SCHEMBL14838625 0.78 IDO1 (0.41) IDO1KDM4EHTTHPGDESR1
SCHEMBL124591 0.77 HDAC6 (0.71) HDAC6TDP1ALOX15CYP3A4THRB
SCHEMBL14515399 0.77 HTT (0.58) HDAC6TDP1CYP3A4SMN1; SMN2ALDH1A1
SCHEMBL356821 0.76 ALDH1A1 (0.50) ALDH1A1SLC6A4IDO1HSD17B10CA1
SCHEMBL3637289 0.76 HDAC6 (0.59) HDAC6TDP1ALOX15CYP3A4THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 HDAC6 477/4885TDP1 3930/4885ALOX15 2102/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 HDAC6 477/4885TDP1 3930/4885ALOX15 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.